🔗 Permalink

Inventor profile of:

Jun Liu

City:

Pacifica, California

Country:

United States

Published Applications:

Last publication date:

2024-10-03

Top Assignees for applications by Jun Liu

The entities that hold a legal rights for patent applications filed by inventor Liu Jun:

Genentech, Inc. 21 South San Francisco, CA United States
NOVARTIS AG 8 Basel, Switzerland
Coherus Biosciences, Inc. 3 Redwood City, CA United States
Genetech, Inc. 2 South San Francisco, CA United States
Novartis, AG 1 , Switzerland

Recent patent applications by Liu Jun

Jun Liu from Pacifica, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-10-03

US20240325559A1

Human necessities

STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS

#2 | 2023-08-24

US20230263895A1

Human necessities

ANTIBODY FORMULATIONS

#3 | 2023-02-21

US15337845

Human necessities

Stable protein compositions and methods of their use

#4 | 2022-02-10

US20220040300A1

Human necessities

Method of filling a container with no headspace

#5 | 2020-06-11

US20200179515A1

Human necessities

ANTIBODY FORMULATIONS

#6 | 2020-01-23

US20200023063A1

Human necessities

COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS

#7 | 2019-11-28

US20190358323A1

Human necessities

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

#8 | 2019-10-17

US20190314517A1

Human necessities

Stable anti-CD79B immunoconjugate formulations

#9 | 2019-08-01

US20190231875A1

Human necessities

REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS

#10 | 2018-08-09

US20180221488A1

Human necessities

ANTIBODY FORMULATIONS

#11 | 2018-02-15

US20180043020A1

Human necessities

METHOD OF REDUCING IMMUNOGENICITY OF DRUG PRODUCTS

#12 | 2017-10-26

US20170304445A1

Human necessities

Method of filling a container with no headspace

#13 | 2017-08-10

US20170224820A1

Human necessities

COMPOSITIONS AND METHODS USEFUL FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS

#14 | 2016-12-22

US20160367675A1

Human necessities

REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS

#15 | 2015-07-16

US20150196642A1

Human necessities

ANTIBODY FORMULATIONS

#16 | 2015-02-12

US20150044198A1

Human necessities

Reduced-viscosity concentrated protein formulations

#17 | 2014-10-16

US20140309403A1

Chemistry; metallurgy

Protein purification methods

#18 | 2013-03-28

US20130078232A1

Human necessities

Compositions and methods useful for stabilizing protein-containing formulations

#19 | 2013-03-21

US20130071384A1

Human necessities

Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody

#20 | 2013-03-07

US20130058958A1

Human necessities

COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS

#21 | 2012-03-29

US20120076783A1

Human necessities

Reduced-viscosity concentrated protein formulations

#22 | 2012-03-15

US20120064086A1

Human necessities

High concentration antibody and protein formulations

#23 | 2010-06-24

US20100158898A1

Chemistry; metallurgy

METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS

#24 | 2010-01-21

US20100015157A1

Human necessities

Antibody formulations

#25 | 2009-11-12

US20090280129A1

Human necessities

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

#26 | 2007-05-24

US20070116700A1

Human necessities

Reduced-viscosity concentrated protein formulations

#27 | 2007-04-19

US20070086995A1

Chemistry; metallurgy

Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations

#28 | 2007-03-08

US20070053900A1

Human necessities

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

#29 | 2006-04-27

US20060088523A1

Human necessities

Antibody formulations

#30 | 2005-08-11

US20050175603A1

Human necessities

Method of reducing viscosity of high concentration protein formulations

#31 | 2005-07-21

US20050158303A1

Chemistry; metallurgy

Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations

#32 | 2005-04-05

US9971511

Reduced-viscosity concentrated protein formulations

InventorID:

126972 ⎘